98%
921
2 minutes
20
Background: The International Society of Urological Pathology (ISUP) revised the Gleason system in 2005 and 2014. The impact of these changes on prostate cancer (PCa) prognostication remains unclear.
Objective: To evaluate if the ISUP 2014 Gleason score (GS) predicts PCa death better than the pre-2005 GS, and if additional histopathological information can further improve PCa death prediction.
Patients And Methods: We conducted a case-control study nested among men in the National Prostate Cancer Register of Sweden diagnosed with non-metastatic PCa 1998-2015. We included 369 men who died from PCa (cases) and 369 men who did not (controls). Two uro-pathologists centrally re-reviewed biopsy ISUP 2014 Gleason grading, poorly formed glands, cribriform pattern, comedonecrosis, perineural invasion, intraductal, ductal and mucinous carcinoma, percentage Gleason 4, inflammation, high-grade prostatic intraepithelial neoplasia (HGPIN) and post-atrophic hyperplasia. Pre-2005 GS was back-transformed using i) information on cribriform pattern and/or poorly formed glands and ii) the diagnostic GS from the registry. Models were developed using Firth logistic regression and compared in terms of discrimination (AUC).
Results: The ISUP 2014 GS (AUC = 0.808) performed better than the pre-2005 GS when back-transformed using only cribriform pattern (AUC = 0.785) or both cribriform and poorly formed glands (AUC = 0.792), but not when back-transformed using only poorly formed glands (AUC = 0.800). Similarly, the ISUP 2014 GS performed better than the diagnostic GS (AUC = 0.808 vs 0.781). Comedonecrosis (AUC = 0.811), HGPIN (AUC = 0.810) and number of cores with ≥50% cancer (AUC = 0.810) predicted PCa death independently of the ISUP 2014 GS.
Conclusion: The Gleason Grading revisions have improved PCa death prediction, likely due to classifying cribriform patterns, rather than poorly formed glands, as Gleason 4. Comedonecrosis, HGPIN and number of cores with ≥50% cancer further improve PCa death discrimination slightly.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784949 | PMC |
http://dx.doi.org/10.2147/CLEP.S339140 | DOI Listing |
Nucl Med Commun
August 2025
Department of Nuclear Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Objective: The aim of this study was to determine the rate of metastasis types in prostate cancer (PCa) patients with bone metastasis and to evaluate the relationship between volumetric parameters obtained from gallium-68 (68Ga) prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) and prostate-specific antigen (PSA) levels.
Materials And Methods: We retrospectively reviewed the images of patients who underwent 68Ga PSMA PET/CT for restaging for recurrent PCa between 2014 and 2019. All detected bone lesions were manually grouped as 'osteoblastic (OB), osteolytic (OL), mixed (M), and radio-occult (RO) lesions' and the number and percentage were determined.
World J Urol
July 2025
Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, 1070, Brussels, Belgium.
Purpose: To compare the accuracy of ISUP grade groups (GG) determined from MRI-targeted and systematic biopsies with radical prostatectomy (RP) specimens using the 2014 and 2019 ISUP recommendations, and to identify predictors of upgrading.
Methods: We analyzed 212 consecutive patients who underwent both MRI-targeted and systematic biopsies followed by RP at the Jules Bordet Institute from October 2019 to January 2025. GG were assigned per 2019 ISUP guidelines, using the highest Gleason score, either from the global score of MRI-targeted lesions (including perilesional cores) or from individual systematic biopsy cores.
Urol J
July 2025
Health Sciences University, Istanbul Training and Research Hospital,Department of Urology, ,Istanbul, ,Turkiye.
Objective: This study aimed to investigate the potential role of systemic inflammatory markers in the management of Prostate Cancer (PCA) with variant pathology.
Materials And Methods: A retrospective analysis was conducted on 302 patients who underwent radical prostatectomy between 2014 and 2023. After applying exclusion criteria, 279 patients were included: 207 with adenocarcinoma and 72 with variant pathologies.
Int J Surg
July 2025
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Background: The pathological assessment of International Society of Urological Pathology (ISUP) nuclear grading is crucial for the management of clear cell renal cell carcinoma (ccRCC). We aimed to develop an artificial intelligence (AI)-based, high-efficiency, and high-accuracy ccRCC ISUP Grading Diagnostic System (RIGDAS) and evaluate its clinical application value.
Methods: In this multicenter, retrospective, diagnostic study, consecutive ccRCC patients who underwent partial or complete nephrectomy between 1 June 2014 and 1 June 2024 across three Chinese hospitals and two public cohorts were included.
Indian J Surg Oncol
April 2025
Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
The objective is to test the role of baseline endogenous testosterone (ET) in discriminating adverse tumor grades and predicting disease progression in prostate cancer (PCa) patients, who harbored organ-confined disease at radical prostatectomy (RP). Between November 2014 and December 2019, data on PCa patients treated with robot-assisted RP at a single tertiary referral center were retrospectively analyzed. Baseline ET levels were coded as abnormal (≤ 350 ng/dL) vs.
View Article and Find Full Text PDF